About Arcellx
Arcellx is a company based in Gaithersburg (United States) founded in 2014 by David Hilbert was acquired by Gilead in February 2026. It operates as a HealthTech. Arcellx has raised $241.84 million across 5 funding rounds from investors including Gilead, LG and Takeda Pharmaceuticals. The company has 163 employees as of December 31, 2024. Arcellx offers products and services including Cell Therapies and D-Domain Technology. Arcellx operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Gaithersburg, United States
- Employees 163 as on 31 Dec, 2024
- Founders David Hilbert
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Arcellx, Inc.
-
Annual Revenue
$107.94 M-2.16as on Dec 31, 2024
-
Net Profit
$-107.35 M-51.86as on Dec 31, 2024
-
EBITDA
$-132.38 M-50.71as on Dec 31, 2024
-
Total Equity Funding
$241.84 M (USD)
in 5 rounds
-
Latest Funding Round
$100 M (USD), Post-IPO
Feb 06, 2023
-
Investors
Gilead
& 23 more
-
Employee Count
163
as on Dec 31, 2024
-
Acquired by
Gilead
(Feb 23, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Arcellx
Arcellx is a publicly listed company on the NASDAQ with ticker symbol ACLX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Arcellx
Arcellx offers a comprehensive portfolio of products and services, including Cell Therapies and D-Domain Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Cell therapies are developed for cancer treatment solutions.
Innovative technology is used for advanced cell therapies.
Unlock access to complete
Unlock access to complete
Leadership Team
16 people
Software Development Team
12 people
Senior Team
6 people
Board Team
5 people
Finance and Accounting
4 people
Human Resources and Administration
4 people
Operations Team
4 people
Sales and Marketing
3 people
Unlock access to complete
Funding Insights of Arcellx
Arcellx has successfully raised a total of $241.84M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $100.0M
- First Round First Round
- Investors Count 23
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2023 | Amount | Post-IPO - Arcellx | Valuation |
investors |
|
| Apr, 2021 | Amount | Series C - Arcellx | Valuation | Samsara BioCapital , CAM Capital | |
| Oct, 2019 | Amount | Series B - Arcellx | Valuation | Quan Capital , Solasta Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Arcellx
Arcellx has secured backing from 24 investors, including venture fund and institutional investors. Prominent investors backing the company include Gilead, LG and Takeda Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are directed toward early and growth stage companies.
|
Founded Year | Domain | Location | |
|
Investment in early-stage companies across AI, biotech, and cleantech sectors with access to global resources.
|
Founded Year | Domain | Location | |
|
Venture capital investment firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Arcellx
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Arcellx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Arcellx Comparisons
Competitors of Arcellx
Arcellx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Arcellx
Frequently Asked Questions about Arcellx
When was Arcellx founded?
Arcellx was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Where is Arcellx located?
Arcellx is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Who is the current CEO of Arcellx?
Rami Elghandour is the current CEO of Arcellx.
Is Arcellx a funded company?
Arcellx is a funded company, having raised a total of $241.84M across 5 funding rounds to date. The company's 1st funding round was a Series B of $85M, raised on Sep 01, 2017.
How many employees does Arcellx have?
As of Dec 31, 2024, the latest employee count at Arcellx is 163.
What is the annual revenue of Arcellx?
Annual revenue of Arcellx is $107.94M as on Dec 31, 2024.
What does Arcellx do?
Arcellx is engaged in the development of innovative cell therapies targeting cancer and autoimmune diseases. The company utilizes its proprietary D-Domain technology along with ddCAR and ARC-SparX platforms to enhance treatment approaches. Operating within the biotechnology sector, Arcellx aims to transform cancer treatment through scientific advancements and collaborative efforts. Its solutions are designed to prioritize patient care while challenging conventional methods in the fight against cancer.
Who are the top competitors of Arcellx?
Arcellx's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Arcellx offer?
Arcellx offers Cell Therapies and D-Domain Technology.
Is Arcellx publicly traded?
Yes, Arcellx is publicly traded on NASDAQ under the ticker symbol ACLX.
Who are Arcellx's investors?
Arcellx has 24 investors. Key investors include Gilead, LG, Takeda Pharmaceuticals, Citadel, and Aju IB Investment.
What is Arcellx's ticker symbol?
The ticker symbol of Arcellx is ACLX on NASDAQ.